Nifurtimox | ||||
CAS NO.: | 23256-30-6 | |||
Chemical Formula: | C10H13N3O5S | |||
Molecular Weight: | 287.2900 | |||
DMF&GMP status: | Please contact us for more details. | Description: |
Nifurtimox is a nitrofuran derivative with antiprotozoal and potential antineoplastic activities. Nifurtimox is reduced by cytosol enzymes or flavin-containing microsomal enzymes to a highly reactive nitro anion free radical; autooxidation of the nitro anion free radical generates cytotoxic superoxide anion (02-). In addition, nifurtimox-derived nitro anion free radicals may alkylate macromolecules such as nucleic acids and proteins, resulting in the disruption of their structure and function.
Nifurtimox is a nitrofuran antibiotic. Nifurtimox has been investigated for the treatment of Sleeping Sickness and Human African Trypanosomiasis. **The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer. |
|
Approvals | ||||
Active Ingredient | Dosage Form; Route | Strength | Proprietary Name | Applicant |
NIFURTIMOX | TABLET;ORAL | 30MG | LAMPIT | BAYER HEALTHCARE PHARMACEUTICALS INC |
NIFURTIMOX | TABLET;ORAL | 120MG | LAMPIT | BAYER HEALTHCARE PHARMACEUTICALS INC |
Patent Data | ||||
Patent No. | Patent Expiration | Drug Substance Claim | Drug Product Claim | Patent Use Code |
N.A. | N.A. | N.A. | N.A. | N.A. |
Exclusive Data | ||||
Exclusivity Code | Exclusivity Expiration | |||
NCE | 08/06/2025 | |||